MicroGEM

MicroGEM democratizes molecular biology by moving complex molecular biology tools out of highly skilled laboratories to non-laboratory settings where they can be used quickly at the point of need. The company’s innovative enzymatic approach to nucleic acid extraction provides the foundation for fast sample preparation suitable for PCR analysis. Coupled with its expertise in microfluidics and synthetic biology, MicroGEM is creating the next generation of person-portable diagnostic devices for the management of infectious diseases and other personalized medicine applications.

The company has received FDA emergency use authorization for the MicroGEM Sal6830 SARS-CoV-2 Saliva Test, the FDA’s first authorized saliva test for COVID-19 using PCR at the point of care. The test provides ‘saliva collection to PCR result’ in 27 minutes.